Overview

A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients

Status:
Completed
Trial end date:
2018-02-16
Target enrollment:
Participant gender:
Summary
Pharmacokinetics and pharmacodynamics study of 2 formulation of insulin glargine (RinGlar® GEROPHARM vers. Lantus® Sanofi-Aventis)
Phase:
N/A
Details
Lead Sponsor:
Geropharm
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc